Biotech

OPT Congress 2027

Starts in 19 weeks

OPT Congress 2027 runs Mar 17–19, 2027 in Boston, United States. It is a Biotech conference expecting about 300 attendees. ConferenceGrid lists 65 speakers and 8 sessions so far.

Lineup updated Oct 29, 2026 · dates verified Aug 27, 2026

OPT Congress is where the oligonucleotide and RNA communities come together to share the science, technologies, and strategies advancing the next generation of nucleic acid therapeutics. Spanning discovery through clinical development and manufacturing, the program features four focused conference tracks, expert-led short courses, and scientific discussions…

Visit the official site
65Speakers
0Sponsors
8Sessions
48Companies · in total

Get alerts for OPT Congress 2027

  • Reminders 90, 30, 7 and 1 day before it starts
  • Add the companies you sell to and see when they sponsor or speak

Free. We email a one-time sign-in link, no password.

Speakers

Programmed at OPT, in alphabetical order.

Adi Gilboa-Geffen
CTO · Eleven Therapeutics
Akash Gupta
Postdoctoral Researcher · Massachusetts Institute of Technology
Alan Horsager
Managing Partner · Concept Bio
Arjan Hada
Senior Scientist · iBio Inc.
Ben Andrews
Independent Consultant; Former Senior Manager, GlaxoSmithKline · Independent Consultant
Ben I Andrews
Independent Consultant · Independent Consultant
Brenda Bass
Distinguished Professor · University of Utah
Brenda Bass, PhD
Distinguished Professor, Biochemistry · University of Utah
Brenda L Bass
Distinguished Professor, Biochemistry · University of Utah
Cecilia Cotta-Ramusino
PhD, Senior Vice President, Technology Development · Tessera Therapeutics Inc.
Chandra Vargeese, PhD
CTO & Head, Platform Discovery Sciences · Wave Life Sciences
Charles Chen
Visiting Lecturer · King's College London
Daniel Anderson
PhD, Professor, Chemical Engineering · Massachusetts Institute of Technology
Daniel Anderson, PhD
Professor, Chemical Engineering · Massachusetts Institute of Technology
Daniel G Anderson
Professor, Chemical Engineering · Massachusetts Institute of Technology
Daniel Glazier
Senior Scientist II, Medicinal Chemistry · Alltrna
David Corey
Prof · Univ of Texas Dallas
David R Corey
Professor, Department of Pharmacology · Univ of Texas Dallas
Debra Miller
Founder & CEO · CureDuchenne
Dmitry Samarsky, PhD
CSO & Board Member · ARNAgen Therapeutics
Elisabeth Gardiner
CSO · Tevard Biosciences
Hagen Cramer
PhD, CTO · QurAlis Corp

Agenda

Selected from 8 sessions.

  • 11:25 am

    Delivery of Oligonucleotide Conjugates: Beyond the Liver

    Efficient delivery remains a central challenge for oligonucleotide therapeutics targeting tissues beyond the liver. Selective, productive uptake in relevant cells is essential to r…

  • 11:55 am

    Engineering Delivery of RNA and Genome Editors

    Nucleic acids have enormous potential to provide therapies for the prevention, treatment, or even cure of human diseases. However, these powerful drug molecules must be delivered i…

  • 12:25 pm

    PANEL DISCUSSION: Strategies and New Modalities for Optimizing Oligo Delivery

    Topics Include: - Advances in Antibody-Oligonucleotide Conjugates (AOCs) and Peptide-Oligonucleotide Conjugates (POCs) - Moving beyond the liver: efficient delivery to muscle, brai…

  • Thursday, March 19, 1:25pm

    Venture Philanthropy in Drug Development from a Rare-Disease Patient-Advocacy Perspective

    CureDuchenne, the leading Duchenne patient advocacy organization, will discuss its initiatives to accelerate the development and regulatory approval of the first drugs to treat Duc…

  • Thursday, March 19, 2:05pm

    Recent Advancements of Oligo-Conjugates Revolutionizing the Field

    Chemical modification is the key to the success of making drugs out of oligonucleotides. Breakthroughs in LNPs formulation and trivalent GalNAc conjugation of chemically modified o…

  • Wednesday, March 18, 4:10pm

    N-of-1 Therapeutics: Progress, Pitfalls, and Prospects for Future Individualized Medicines

    Successes in oligonucleotide therapeutics have spurred the creation of bespoke therapies for rare genetic conditions, even for single patients. This talk will review lessons, chall…

  • Wednesday, March 18, 4:50pm

    ADAR RNA Editing: Applying Current Knowledge to Future Applications

    Much is known about biochemical properties of ADAR RNA editing enzymes from decades of in vitro studies, but how these properties correlate with in vivo editing is not always clear…

  • TBA

    Delivery of Circular RNA to New Tissues

Quick answers

When is OPT Congress 2027?
OPT Congress 2027 runs Mar 17–19, 2027 in Boston, United States.
Where is OPT Congress 2027 held?
OPT Congress 2027 is held in Boston, United States.
Who is speaking at OPT Congress 2027?
ConferenceGrid lists 65 speakers, including Adi Gilboa-Geffen (CTO, Eleven Therapeutics), Akash Gupta (Postdoctoral Researcher, Massachusetts Institute of Technology) and Alan Horsager (Managing Partner, Concept Bio).
Company intelligence

An audience of 48 companies, parsed from the program.

48 companies in attendance.

The numbers below are derived from the speakers, sponsors, and exhibitors on this page, cross-referenced into one ledger. They are the only thing here that 10times.com cannot tell you.

Who's in the room
0All threespeak · spons · exh
0Sponsoringsponsor only
48Speakingspeaker only
Speakers by seniority

55% of the speakers carry senior titles: C-suite, Founder, VP, or Director-level.

  • C-suite1117%
  • Founder / Owner711%
  • VP-level711%
  • Director / Head of1117%
  • Manager / Lead12%
  • Engineer · IC12%
  • Research / Science69%
  • Advisor / Investor12%
  • Other roles2031%

Of 65 speakers · classified by free-text title

Most-represented companies
#CompanyRolesSpeakers
1Massachusetts Institute of Technology4
2University of Utah4
3AstraZeneca3
4Ionis Pharmaceuticals Inc3
5ARNAY Sciences LLC2
6Biologic Insights LLC2
7CREATE Medicines2
8HDR2
9Independent Consultant2
10The Scripps Research Institute2
11Univ of Texas Dallas2
12AIRNA1
13Alltrna1
14Alnylam Pharmaceuticals1
Sponsors by tier

Tiers were not disclosed for this event.

In the same series

Prior and forthcoming editions